Real-world use of ixekizumab for axial spondyloarthritis treatment in Spain (ESPADA study)

20260 citationsJournal Articlegold Open Access

Authors

Cristina Campos · Hospital General Universitario De Valencia

Ma Concepción Fito-Manteca · Universidad de Navarra

Cristina Valero-Martínez · Hospital Universitario de La Princesa

Sara García-Carazo

Raquel Almodóvar · Hospital Universitario Fundación Alcorcón

Silvia Díaz-Cerezo · Eli Lilly (Spain)

Sebastián Moyano · Eli Lilly (Spain)

Abstract

Most axSpA patients treated with IXE had long-standing, highly active disease involving multiple domains and prior multiple domains and prior b/tsDMARDs (b/tsDMARD) exposure. Despite this, half remained on IXE at 1 year with improved disease activity, highlighting its potential as a treatment option in daily practice.

Topics & Keywords

Spondyloarthritis Studies and Treatments Rheumatoid Arthritis Research and Therapies Spine and Intervertebral Disc Pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Frontiers in Medicine

Volume 12, pp. 1704081-1704081

DOI: 10.3389/fmed.2025.1704081

Field-Weighted Citation Impact: 0.00